Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced

[News]

Ipsen today announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor, in advanced endometrial cancer.

More... (http://www.news-medical.net/news/20091125/Initiation-of-Phase-II-clinical-trial-to-evaluate-the-efficacy-of-BN83495-announced.aspx)